improving the half-life and efficacy of ADCs through strategies like the use of albumin-binding domains or small-format antibodies is an area of active research. Design principles for bispecific ...

Recent advances in biotechnology have fuelled the development of bispecific antibodies. However, there still remains a number of development challenges for those working in bioprocessing or cell line ...

Researchers from Shanghai Institute of Biological Products Co. Ltd. published details on the development and preclinical characterization of novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 ...

Generates high-purity antibodies in any format (scFv, VHH, Fab, etc.) at affordable prices. Bispecific Antibody Production Service: Produces recombinant bsAbs in various formats.

The company had completed a phase 1 trial of CDX-585, a bispecific antibody targeting PD-1 and ILT4 in patients with advanced or metastatic solid tumors that had not been halted by standard-of ...

LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer ...

improving the half-life and efficacy of ADCs through strategies like the use of albumin-binding domains or small-format ...

Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...

GlycoMimetics (GLYC) announced it has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company.